The CGI-S showed a trend toward improvement over placebo in the arbaclofen group ( p = 0.063) but this was the only measure showing a strong trend, and given the multiple comparisons, this result alone is difficult to interpret as meaningful.
As a matter of fact, subjects with a baseline-impaired DLCO (<80% pred at T0; n = 38) showed a trend in improvement at 6 months ( p = 0.063).
Outer quadrant lesion and time interval between surgery and radiotherapy showed a trend associated with displacement in the lateromedial ( p =0.063) and superoinferior ( p =0.057) directions ( Supplementary Table 1 ).
After ART, most biomarkers of inflammation significantly decreased (p<0.01), except for D-dimer which showed a trend toward a significant decrease (p = 0.063).
In this same non-CRC cohort, the HER2+ EpCAM+ CTC count showed a trend toward decrease at study Week 12 in 6 patients status post 3 doses of AdHER2 DC vaccine (P=0.063).
This effect occurred because the intervention group scored significantly worse than the community group, p = 0.031, and the waitlist group showed a trend toward worse performance than the community group, p = 0.063.
It was 0.757 (95%CI = 0.672–0.829) which was still significantly higher than that of HBV DNA (AUROC 0.604, 95%CI = 0.513–0.690; P = 0.013), and showed a trend to be better than those of LRM and qHBsAg level (AUROC 0.670, 95%CI = 0.581–0.751, P = 0.063; 0.670, 95%CI = 0.581–0.751, P = 0.063 respectively) ( Table 4 ).
However, the worst performing sprinters (first tertile of physical performance) showed a trend for significant (p = 0.063) higher post-exercise urinary Cr levels compared to the most efficient sprinters (third tertile) ( Figure 4 ).
BMP4 and BMP6 also showed a trend of increased Ki67 mRNA (P = 0.063 and 0.052, respectively).
Gabarapl1 showed a trend towards elevation ( p = 0.063) with WS patients showing the greatest fold change (1.7) compared with controls (1.1) or WL (1.5) patients.
TRAIL and Gal1 showed a trend towards significance (median 92.16 vs 56.21, p = 0.063 and mean 32,756.72 vs 27,097.95, p = 0.063 respectively).
TAR also showed a trend toward protection in adjusted analysis (HR, 0.381, 95% CI, 0.138-1.053, P = .063).
Notably, AKI scores showed a trend toward a significant reduction in the subgroup ( P = 0.063).
Regarding the HbA1c levels, %IRF change showed a trend ( p = 0.063).
Baseline 0800 h insulin concentrations (0 min DCP sample) also showed a trend towards being lower in treated ponies (P = 0.063), with a median (IQR) value of 8 μIU/mL (4–95) compared to 52 μIU/mL (10–189) for controls.
However, a previous study in the Caucasian population (Spain) showed a trend between the FCER1B rs573790-CC genotype (OR = 4.26; 95%CI = 1.01–26.98; p = .063) and a better response in reducing exacerbations. 33 Another author also associated this genotype with asthma and aspirin-exacerbated respiratory disease in a mestizo population (Mexico). 34 The Fc region of IgG enhances drug stability and prolongs its half-life, improving its pharmacokinetics. 35 The Fc region of human IgG1 binds selectively to Fc-gamma receptors (FcγR) on the surface of B lymphocytes, dendritic cells (DCs), and macrophages.
PD-L1 expression ≥ 1% showed a trend toward improved OS (HR 3.72, p = 0.063).
27%; P = 0.043), but multivariate P ‐value was nonsignificant ( P = 0.73); similarly, PFS showed a trend to improvement in univariate analysis (6.2 vs. 3.7 months; P = 0.063) but was nonsignificant in multivariate analysis; OS was not significantly different in patients who did and did not receive immune checkpoint blockade.
Diarrhea occurrence decreased quadratically ( p < 0.05) and showed a trend toward a linear reduction ( p = 0.063).
Kaplan–Meier analysis of the AML patients showed a trend toward worse prognosis among patients exhibiting above-median IQGAP1 expression ( p = 0.063) (Fig. 1 H).
Although cardiovascular death showed a trend (22.8 vs. >24 months, p=0.063), all-cause mortality was significantly higher in CMD patients (21.6 vs. >24 months, p=0.041).
After adjusting for baseline differences using IPTW, TEVAR showed a trend towards reduced mortality with an IPTW-adjusted hazard ratio (HR) of 0.53 [95% CI: 0.27–1.04, P = 0.063] (Fig. 6 a).
PIU+ showed a trend toward reduced negative emotion between BL and WS3 ( p = 0.063) and significant self-esteem increases from BL to WS2 ( p = 0.043) and WS3 ( p = 0.042).
For tumors 5–10 cm, chemotherapy showed a trend toward improved survival (HR = 0.45, 95% CI: 0.19–1.05, p = 0.063).
Multivariate analysis identified CAT as an independent factor for exacerbation (OR = 1.15, 95% CI = 1.00–1.33, p = 0.047), while PNI showed a trend of being associated with exacerbation (OR = 0.73, 95% CI =0.52–1.02, p = 0.063).